Eisai, a pharmaceutical company, has shared new clinical data from a study called Clarity AD. This study looked at adults with early Alzheimer’s disease who don’t carry a specific gene called apolipoprotein E ε4 or carry only one copy of it. The data was presented at a medical conference in Berlin. The study found that patients who took lecanemab, a medication for Alzheimer’s, for up to 48 months continued to see benefits. These benefits were compared to a group of patients who did not take the medication. The treatment also reduced the risk of the disease getting worse by 32% over the same period. Robert Sands, a medical expert from Eisai, said that these findings add to the growing evidence that lecanemab can help eligible patients. He emphasized the importance of long-term data to better understand the effects of continuous treatment. Eisai is committed to researching and innovating to find solutions for Alzheimer’s disease. In the EU and UK, lecanemab is approved for patients with mild memory problems or mild dementia due to Alzheimer’s who don’t carry the specific gene or carry only one copy of it. Common side effects include reactions to the infusion, brain swelling or bleeding, falls, headaches, and other related brain conditions.